C07K 14/7056
Lectin superfamily
Official title: {Lectin superfamily, e.g. CD23, CD72}
C07K14/7056 (Lectin superfamily) appears on 335 US grants and 495 published applications in this corpus.
Search patents in C07K- Granted patents
- 335
- Published applications
- 495
- Assignees
- 296
- Inventors
- 1,139
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 2 | 0 |
| 1993 | 5 | 0 |
| 1994 | 4 | 0 |
| 1995 | 9 | 0 |
| 1996 | 3 | 0 |
| 1997 | 13 | 0 |
| 1998 | 25 | 0 |
| 1999 | 19 | 0 |
| 2000 | 12 | 0 |
| 2001 | 15 | 0 |
| 2002 | 10 | 11 |
| 2003 | 10 | 18 |
| 2004 | 2 | 12 |
| 2005 | 0 | 13 |
| 2006 | 8 | 9 |
| 2007 | 5 | 8 |
| 2008 | 6 | 5 |
| 2009 | 1 | 6 |
| 2010 | 6 | 12 |
| 2011 | 5 | 10 |
| 2012 | 3 | 10 |
| 2013 | 3 | 10 |
| 2014 | 6 | 8 |
| 2015 | 4 | 10 |
| 2016 | 6 | 10 |
| 2017 | 6 | 11 |
| 2018 | 8 | 20 |
| 2019 | 15 | 21 |
| 2020 | 14 | 42 |
| 2021 | 18 | 40 |
| 2022 | 25 | 44 |
| 2023 | 13 | 47 |
| 2024 | 23 | 55 |
| 2025 | 17 | 34 |
| 2026 | 14 | 29 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Multimeric proteins for detecting a carbohydrate and/or treating a siglec-mediated disorder25 Aug 2026US 12,715,903 B2Palleon Pharmaceuticals Inc.
- Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease4 Aug 2026US 12,698,476 B2National University of Singapore
- Anti-MUC1 compositions and methods of use21 Jul 2026US 12,686,726 B2Poseida Therapeutics, Inc.
- Non-human animals comprising a humanized ASGR1 locus14 Jul 2026US 12,680,107 B2Regeneron Pharmaceuticals, Inc.
- Genetically engineered hematopoietic stem cells and uses thereof12 May 2026US 12,622,929 B2SyzygyMed Inc.
- Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof3 Sep 2026US 2026/0256839 A1Century Therapeutics, Inc.
- Engineered natural killer cells with enhanced antitumor memory responses3 Sep 2026US 2026/0258360 A1Board of Regents, The University of Texas System
- Tcr molecules targeting kras mutation, cells and use of tcr molecules and cells20 Aug 2026US 2026/0240907 A1Beijing Dcty Biotech Co., Ltd.
- Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies20 Aug 2026US 2026/0242801 A1ImmunityBio, Inc.
- Mir-326 for the treatment of cancer13 Aug 2026US 2026/0234615 A1FundacióN Para La InvestigacióN BioméDica Del Hospital Universitario RamóN Y Cajal
Most cited
By later US patents
- Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2109US 5,789,573 AIsis Pharmaceuticals, Inc. · 1998
- Oligonucleotide modulation of cell adhesion96US 5,514,788 AIsis Pharmaceuticals, Inc. · 1996
- Treatment of cancer using a CD33 chimeric antigen receptor86US 9,777,061 B2Novartis AG · 2017
- Cloned genes which encode ELAM-179US 5,081,034 AThe Brigham and Women S Hospital, Inc. · 1992
- Method of determining a site of inflammation utilizing elam-1 ligands77US 5,143,712 AGlycomed Incorporated · 1992